AstraZeneca To Pay $11M To Settle Toprol-XL Antitrust Claims
AstraZeneca Pharmaceuticals LP on Tuesday agreed to pay $11 million to settle claims by a proposed class of indirect purchasers of hypertension drug Toprol-XL that the drugmaker used sham patent litigation...To view the full article, register now.
Already a subscriber? Click here to view full article